Research ExplorerPublicationsMonitoring in metastatic breast cancer: is imaging outdated ...

Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?

Standard

Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells? / Alunni-Fabbroni, Marianna; Müller, Volkmar; Fehm, Tanja; Janni, Wolfgang; Rack, Brigitte.

In: BREAST CARE, Vol. 9, No. 1, 01.02.2014, p. 16-21.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Alunni-Fabbroni, M, Müller, V, Fehm, T, Janni, W & Rack, B 2014, 'Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?', BREAST CARE, vol. 9, no. 1, pp. 16-21. https://doi.org/10.1159/000360438

APA

Alunni-Fabbroni, M., Müller, V., Fehm, T., Janni, W., & Rack, B. (2014). Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells? BREAST CARE, 9(1), 16-21. https://doi.org/10.1159/000360438

Vancouver

Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells? BREAST CARE. 2014 Feb 1;9(1):16-21. https://doi.org/10.1159/000360438

Bibtex

@article{dd5439d2520b4dd98e8a1fbc59b52253,
title = "Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?",
abstract = "In clinical practice imaging technologies such as computed tomography (CT), positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) are well-established methods for monitoring metastatic breast cancer (MBC) patients and for assessing therapeutic efficacy. However, several weeks of treatment are required before these technologies can offer any reliable information on effective disease regression, and, in the meanwhile, the patients are exposed to potentially unnecessary therapy. Circulating tumor cells (CTCs) have been shown to be powerful prognostic and predictive markers and provide clinicians with valuable information. However, in one clinical trial, an early change of chemotherapy based on CTC detection did not result in improved survival. Currently, CTC detection outside clinical trials should be limited to selected clinical situations, i.e. increased treatment toxicity or as risk estimation.",
author = "Marianna Alunni-Fabbroni and Volkmar M{\"u}ller and Tanja Fehm and Wolfgang Janni and Brigitte Rack",
year = "2014",
month = feb,
day = "1",
doi = "10.1159/000360438",
language = "English",
volume = "9",
pages = "16--21",
journal = "BREAST CARE",
issn = "1661-3791",
publisher = "S. Karger AG",
number = "1",

}

RIS

TY - JOUR

T1 - Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?

AU - Alunni-Fabbroni, Marianna

AU - Müller, Volkmar

AU - Fehm, Tanja

AU - Janni, Wolfgang

AU - Rack, Brigitte

PY - 2014/2/1

Y1 - 2014/2/1

N2 - In clinical practice imaging technologies such as computed tomography (CT), positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) are well-established methods for monitoring metastatic breast cancer (MBC) patients and for assessing therapeutic efficacy. However, several weeks of treatment are required before these technologies can offer any reliable information on effective disease regression, and, in the meanwhile, the patients are exposed to potentially unnecessary therapy. Circulating tumor cells (CTCs) have been shown to be powerful prognostic and predictive markers and provide clinicians with valuable information. However, in one clinical trial, an early change of chemotherapy based on CTC detection did not result in improved survival. Currently, CTC detection outside clinical trials should be limited to selected clinical situations, i.e. increased treatment toxicity or as risk estimation.

AB - In clinical practice imaging technologies such as computed tomography (CT), positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) are well-established methods for monitoring metastatic breast cancer (MBC) patients and for assessing therapeutic efficacy. However, several weeks of treatment are required before these technologies can offer any reliable information on effective disease regression, and, in the meanwhile, the patients are exposed to potentially unnecessary therapy. Circulating tumor cells (CTCs) have been shown to be powerful prognostic and predictive markers and provide clinicians with valuable information. However, in one clinical trial, an early change of chemotherapy based on CTC detection did not result in improved survival. Currently, CTC detection outside clinical trials should be limited to selected clinical situations, i.e. increased treatment toxicity or as risk estimation.

U2 - 10.1159/000360438

DO - 10.1159/000360438

M3 - SCORING: Journal article

C2 - 24803882

VL - 9

SP - 16

EP - 21

JO - BREAST CARE

JF - BREAST CARE

SN - 1661-3791

IS - 1

ER -